vantuylen

[From The Body, July 3, 2018] “Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks — the drug’s price tag, which has surged in recent years, and changes in insurance coverage that […]

[From UNAIDS, June 29, 2018] “At UNAIDS’ 42nd Programme Coordinating Board meeting, which took place in Geneva, Switzerland, on 26–28 June, Board members expressed their support for UNAIDS and underscored the critical role that the organization has to play in ending the AIDS epidemic.” For more, click here.

[From AIDSMAP, June 28, 2018] “Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in HIV Medicine. Although the two drugs showed similar virological efficacy, people treated with efavirenz were significantly more likely than individuals taking rilpivirine to stop taking

[From The Guardian, June 28, 2018] “Scientists have provided explanation why Nigeria, Russia, and Florida in the United States (US) have worst outcomes for Human Immuno-deficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) in the world. According to special reports by the journal Science, each has had difficulty mounting an effective response to HIV/AIDS at a

[From The Conversation, June 27, 2018] “Fifteen years ago drugs were introduced that, for the first time, prevented mothers from transmitting the HIV virus to their babies. The drugs meant that children born to mothers infected with the virus could live long and fruitful lives despite being HIV positive. Since then researchers have studied the